TALPHERA, INC.
TLPHDrugs in Pipeline
10
Phase 3 Programs
6
Upcoming Catalysts
1
Next Catalyst
Jan 1, 2027
33wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
sufentanil sublingual 30 mcg tablet
Moderate-to-severe Acute Pain
morphine IV PCA
Post-Operative Pain
sufentanil sublingual tablet 30 mcg
Acute Moderate-to-severe Pain
Zalviso™ 15 mcg
Moderate-to-severe Acute Pain
Sufentanil Tablet 30 mcg
Post-Operative Pain
Sufentanil NanoTab PCA System/15 mcg
Pain, Postoperative
Oral sufentanil
Major Upper or Lower Abdominal Surgery
Sufentanil NanoTab
Post Operative Pain
Sufentanil NanoTab 20 mcg
Acute Pain
Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)
Sedation
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
sufentanil sublingual 30 mcg tablet | Phase 3 | Moderate-to-severe Acute Pain | - | - |
morphine IV PCA | Phase 3 | Post-Operative Pain | - | - |
sufentanil sublingual tablet 30 mcg | Phase 3 | Acute Moderate-to-severe Pain | - | - |
Zalviso™ 15 mcg | Phase 3 | Moderate-to-severe Acute Pain | - | - |
Sufentanil Tablet 30 mcg | Phase 3 | Post-Operative Pain | - | - |
Sufentanil NanoTab PCA System/15 mcg | Phase 3 | Pain, Postoperative | - | - |
Oral sufentanil | Phase 2 | Major Upper or Lower Abdominal Surgery | - | - |
Sufentanil NanoTab | Phase 2 | Post Operative Pain | - | - |
Sufentanil NanoTab 20 mcg | Phase 2 | Acute Pain | - | - |
Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03) | Phase 2 | Sedation | - | - |